Research location
Jiamusi
Heilongjiang, China
Advertisement
Research activity in Jiamusi
Heilongjiang, ChinaCureCurrent currently publishes aggregate city-level research activity for this location: 16 trials and 16 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Jiamusi
16 linked trials · page 1 of 1A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)NCT07190248 · 2025-10-08 · 1 site observation
RECRUITING
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerNCT07043725 · 2025-09-15 · 1 site observation
RECRUITING
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerNCT07047365 · 2025-07-25 · 1 site observation
RECRUITING
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast CancerNCT07008976 · 2025-07-07 · 1 site observation
RECRUITING
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)NCT06345729 · 2024-05-24 · 1 site observation
RECRUITING
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureNCT06300177 · 2024-03-28 · 1 site observation
RECRUITING
Multicenter Study on Early Arterial Changes in Prediabetic Patients Evaluated by Ultra-High-Frequency UltrasoundNCT07271745 · 2025-12-15 · 1 site observation
NOT_YET_RECRUITING
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)NCT07005128 · 2025-08-18 · 1 site observation
ACTIVE_NOT_RECRUITING
A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT06789289 · 2025-03-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabNCT06211036 · 2024-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung CancerNCT05990127 · 2023-11-14 · 1 site observation
NOT_YET_RECRUITING
Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.NCT05922345 · 2023-06-08 · 1 site observation
UNKNOWN
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC PatientsNCT05443646 · 2022-09-23 · 1 site observation
UNKNOWN
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerNCT05365178 · 2022-07-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerNCT05353257 · 2022-05-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLCNCT04033354 · 2019-08-14 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.